BioStock: Xintela approaches the market with EQSTEM
Drug development company Xintela continues to take steps towards the market with the stem cell product EQSTEM. Recently, a preclinical study was completed showing that the product reduces lameness in horses that have osteoarthritis due to joint injury. Based on these results, the company continues to develop EQSTEM towards market approval. BioStock reached out to Professor Casper Lindegaard, who was involved in the horse study with EQSTEM, for a comment.
Read the full interview with Professor Casper Lindegaard at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se